[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647434":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":72,"collaborators":11,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":11,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":11,"enrollmentInfo":83,"targetDuration":11,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":11,"overallStatus":92,"whyStopped":11,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Shandong Suncadia Medicine Co., Ltd.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group A: HRS-2129 Tablet","EXPERIMENTAL",null,[13],"Drug: HRS-2129 Tablet",{"label":15,"type":10,"description":11,"interventionNames":16},"Treatment group B: HRS-2129 Tablet",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Treatment group C: HRS-2129 Tablet Placebo","PLACEBO_COMPARATOR",[21],"Drug: Placebo",[23,28,31],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","HRS-2129 Tablet","HRS-2129 Tablet; high dose",[9],{"type":24,"name":25,"description":29,"armGroupLabels":30,"otherNames":11},"HRS-2129 Tablet; low dose",[15],{"type":24,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"Placebo","HRS-2129 Tablet Placebo",[18],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Lei Tang","CONTACT","+0518-82342973","lei.tang.lt31@hengrui.com",[42,59],{"facility":43,"status":11,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The Third Affiliated Hospital of Sun Yat-sen University","Guangzhou","Guangdong","510630","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56],{"name":57,"role":58,"phone":11,"phoneExt":11,"email":11},"Yunfeng Pan","PRINCIPAL_INVESTIGATOR",{"facility":60,"status":11,"city":61,"state":62,"zip":63,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School","Nanjing","Jiangsu","210008",{"type":50,"coordinates":65},[66,67],118.77778,32.06167,{"lat":67,"lon":66},[70],{"name":71,"role":58,"phone":11,"phoneExt":11,"email":11},"Lingyun Sun",{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100647434","phase-2-clinical-study-of-hrs-2129-for-acute-gouty-arthritis-100647434",false,"NCT07706777","Clinical Study of HRS-2129 for Acute Gouty Arthritis","Clinical Study on Safety and Efficacy of HRS-2129 for Acute Gouty Arthritis","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent\n2. Subjects requiring Acute gouty arthritis\n3. Target joint VAS pain score ≥ 50 mm (screening)\n\nExclusion Criteria:\n\n1. Subjects with a history of severe allergies\n2. Subjects with nervous system disease\n3. Subjects with a history of mental illness\n4. Subjects with abnormal liver and renal function\n5. Subjects with poorly controlled hypertensive\n6. QTc：\\>450ms（male），\\>470ms（female）\n7. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)\n8. The investigators determined that other conditions were inappropriate for participation in this clinical trial","ALL","18 Years",{"count":84,"type":85},90,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.",[91],"Acute Gouty Arthritis","NOT_YET_RECRUITING","2026-07-15",{"date":95,"type":96},"2026-07-16","ACTUAL",{"date":98,"type":85},"2026-07",{"date":100,"type":85},"2026-11",{"name":5,"class":6},2]